380
Participants
Start Date
February 6, 2018
Primary Completion Date
June 20, 2022
Study Completion Date
June 30, 2027
Nivolumab & Ipilimumab
"Combination Therapy: Cohort 1: Nivolumab 1 mg/kg + ipilimumab 3 mg/kg every 3 weeks for a maximum of 4 cycles . Cohort 2 : Nivolumab 3mg/kg + ipilimumab 1mg/kg every 3 weeks for a maximum of 4 cycles.~Treatment free gap after last combination dose : Cohort 1: 6 weeks; Cohort 2: 3 weeks~Monotherapy: 480 mg flat dose of nivolumab every 4 weeks for up to 10 cycles, or until progression, unacceptable toxicity or withdrawal of consent"
University College London Hospital, London
Collaborators (1)
Bristol-Myers Squibb
INDUSTRY
University College, London
OTHER